Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Angiodynamics Inc (ANGO)

Angiodynamics Inc (ANGO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

AngioDynamics Reports Tomorrow But the Guidance Will Matter More Than the Quarter

AngioDynamics (NASDAQ: ANGO) reports fiscal Q3 2026 earnings before market open on April 2, 2026, with analysts expecting a loss of $0.11 per share on revenue of approximately $76.77 million. The medical device company faces a critical test as investors assess whether its minimally invasive vascular and oncology platforms can sustain recent momentum while navigating profitability challenges. With the stock trading at $11.94 and analysts maintaining a bullish stance despite deteriorating sentiment, this report will determine whether ANGO can continue its pattern of beating estimates or if margin pressures will finally catch up.

AngioDynamics is a medical device company specializing in minimally invasive treatment options for...

Fundamentals

See More
  • Market Capitalization, $K 424,947
  • Shares Outstanding, K 41,217
  • Annual Sales, $ 292,500 K
  • Annual Income, $ -33,990 K
  • EBIT $ -22 M
  • EBITDA $ 4 M
  • 60-Month Beta 0.43
  • Price/Sales 1.68
  • Price/Cash Flow 24.52
  • Price/Book 2.79

Options Overview Details

View History
  • Implied Volatility 47.55% (-17.90%)
  • Historical Volatility 54.47%
  • IV Percentile 4%
  • IV Rank 13.70%
  • IV High 106.24% on 07/14/25
  • IV Low 38.24% on 10/23/25
  • Expected Move (DTE 13) 0.78 (7.58%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 678
  • Volume Avg (30-Day) 262
  • Put/Call OI Ratio 2.17
  • Today's Open Interest 5,809
  • Open Int (30-Day) 2,382
  • Expected Range 9.53 to 11.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 05/31/26
See More
  • Average Estimate $-0.07
  • Number of Estimates 2
  • High Estimate $-0.07
  • Low Estimate $-0.07
  • Prior Year $-0.03
  • Growth Rate Est. (year over year) -133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.29 +0.19%
on 04/02/26
11.95 -13.76%
on 04/01/26
-1.05 (-9.24%)
since 03/02/26
3-Month
9.72 +6.07%
on 01/12/26
13.37 -22.89%
on 01/05/26
-2.37 (-18.69%)
since 01/02/26
52-Week
8.36 +23.33%
on 08/08/25
13.99 -26.30%
on 12/04/25
-0.55 (-5.06%)
since 04/02/25

Most Recent Stories

More News
AngioDynamics: Fiscal Q3 Earnings Snapshot

AngioDynamics: Fiscal Q3 Earnings Snapshot

ANGO : 10.31 (-13.65%)
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

Med Tech segment delivered its sixth consecutive quarter of double-digit growth Strong adjusted EBITDA Third consecutive quarter the Company raised full year FY 2026...

ANGO : 10.31 (-13.65%)
AngioDynamics Reports Tomorrow But the Guidance Will Matter More Than the Quarter

Barchart Research What to Expect from ANGO Earnings ANGO Generated April 1, 2026 Current Price $11.94 EPS Estimate $$-0.11 Consensus Rating Strong Buy Average Move 16.42% AngioDynamics Reports Tomorrow...

ANGO : 10.31 (-13.65%)
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and...

ANGO : 10.31 (-13.65%)
U.S. Jobs Figures Issued in Short Week

MondayFeatured Earnings Maze Therpautics (NASDAQ:MAZE) (Q4) EPS for loss of 73 cents, compared ...

AYI : 265.39 (-7.52%)
MKC : 48.85 (+0.97%)
FDS : 227.68 (+1.25%)
MSM : 90.32 (-1.34%)
CAG : 15.72 (+1.29%)
NKE : 44.19 (-0.99%)
PRGS : 25.76 (+2.67%)
POET : 6.11 (+9.11%)
LW : 39.35 (+2.26%)
ANGO : 10.31 (-13.65%)
MAZE : 28.71 (-1.17%)
LNN : 103.02 (-12.06%)
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and...

ANGO : 10.31 (-13.65%)
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and...

ANGO : 10.31 (-13.65%)
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

Growing Clinical Evidence and Physician Adoption Broaden NanoKnife IRE Technology as Treatment Option for Major Solid Tumor Types

ANGO : 10.31 (-13.65%)
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence

ANGO : 10.31 (-13.65%)
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio

ANGO : 10.31 (-13.65%)

Business Summary

AngioDynamics Inc. designs, manufactures and sells a wide range of medical, surgical and diagnostic devices. The devices are generally used in minimally invasive, image-guided procedures. AngioDynamics product offerings fall within three Global Business Units, namely Oncology/Surgery, Endovascular Therapies...

See More

Key Turning Points

3rd Resistance Point 13.04
2nd Resistance Point 12.48
1st Resistance Point 11.40
Last Price 10.31
1st Support Level 9.76
2nd Support Level 9.20
3rd Support Level 8.12

See More

52-Week High 13.99
Fibonacci 61.8% 11.84
Fibonacci 50% 11.17
Fibonacci 38.2% 10.51
Last Price 10.31
52-Week Low 8.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.